×
S&P 500   3,786.40 (-1.02%)
DOW   30,613.95 (-1.55%)
QQQ   284.18 (+0.73%)
AAPL   139.83 (+0.65%)
MSFT   259.87 (+0.11%)
META   165.72 (+3.56%)
GOOGL   2,235.45 (+2.79%)
AMZN   112.96 (+3.10%)
TSLA   689.40 (+1.12%)
NVDA   148.93 (+2.55%)
NIO   21.71 (+1.64%)
BABA   116.69 (+0.59%)
AMD   74.56 (+1.21%)
MU   56.24 (+4.83%)
CGC   2.66 (-5.34%)
T   20.93 (-1.78%)
GE   61.23 (-3.64%)
F   11.07 (-2.21%)
DIS   95.81 (-0.34%)
AMC   12.71 (-6.06%)
PFE   50.73 (-3.02%)
PYPL   73.86 (+3.45%)
NFLX   183.55 (+2.00%)
S&P 500   3,786.40 (-1.02%)
DOW   30,613.95 (-1.55%)
QQQ   284.18 (+0.73%)
AAPL   139.83 (+0.65%)
MSFT   259.87 (+0.11%)
META   165.72 (+3.56%)
GOOGL   2,235.45 (+2.79%)
AMZN   112.96 (+3.10%)
TSLA   689.40 (+1.12%)
NVDA   148.93 (+2.55%)
NIO   21.71 (+1.64%)
BABA   116.69 (+0.59%)
AMD   74.56 (+1.21%)
MU   56.24 (+4.83%)
CGC   2.66 (-5.34%)
T   20.93 (-1.78%)
GE   61.23 (-3.64%)
F   11.07 (-2.21%)
DIS   95.81 (-0.34%)
AMC   12.71 (-6.06%)
PFE   50.73 (-3.02%)
PYPL   73.86 (+3.45%)
NFLX   183.55 (+2.00%)
S&P 500   3,786.40 (-1.02%)
DOW   30,613.95 (-1.55%)
QQQ   284.18 (+0.73%)
AAPL   139.83 (+0.65%)
MSFT   259.87 (+0.11%)
META   165.72 (+3.56%)
GOOGL   2,235.45 (+2.79%)
AMZN   112.96 (+3.10%)
TSLA   689.40 (+1.12%)
NVDA   148.93 (+2.55%)
NIO   21.71 (+1.64%)
BABA   116.69 (+0.59%)
AMD   74.56 (+1.21%)
MU   56.24 (+4.83%)
CGC   2.66 (-5.34%)
T   20.93 (-1.78%)
GE   61.23 (-3.64%)
F   11.07 (-2.21%)
DIS   95.81 (-0.34%)
AMC   12.71 (-6.06%)
PFE   50.73 (-3.02%)
PYPL   73.86 (+3.45%)
NFLX   183.55 (+2.00%)
S&P 500   3,786.40 (-1.02%)
DOW   30,613.95 (-1.55%)
QQQ   284.18 (+0.73%)
AAPL   139.83 (+0.65%)
MSFT   259.87 (+0.11%)
META   165.72 (+3.56%)
GOOGL   2,235.45 (+2.79%)
AMZN   112.96 (+3.10%)
TSLA   689.40 (+1.12%)
NVDA   148.93 (+2.55%)
NIO   21.71 (+1.64%)
BABA   116.69 (+0.59%)
AMD   74.56 (+1.21%)
MU   56.24 (+4.83%)
CGC   2.66 (-5.34%)
T   20.93 (-1.78%)
GE   61.23 (-3.64%)
F   11.07 (-2.21%)
DIS   95.81 (-0.34%)
AMC   12.71 (-6.06%)
PFE   50.73 (-3.02%)
PYPL   73.86 (+3.45%)
NFLX   183.55 (+2.00%)
NASDAQ:ROIV

Roivant Sciences Stock Forecast, Price & News

$4.51
+0.09 (+2.04%)
(As of 07/5/2022 01:38 PM ET)
Add
Compare
Today's Range
$4.19
$4.58
50-Day Range
$2.81
$4.79
52-Week Range
$2.52
$16.76
Volume
24,199 shs
Average Volume
1.01 million shs
Market Capitalization
$3.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

Roivant Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
167.3% Upside
$12.00 Price Target
Short Interest
Bearish
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Roivant Sciences in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$1.29 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($1.17) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.97 out of 5 stars

Medical Sector

534th out of 1,428 stocks

Pharmaceutical Preparations Industry

254th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Roivant Sciences logo

About Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Roivant Sciences (NASDAQ:ROIV) PT Raised to $7.00
Analyst Ratings for Roivant Sciences
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Roivant Sciences (NASDAQ:ROIV) Trading Down 2.3%
Roivant Sciences (NASDAQ:ROIV) Trading Down 2.3%
Roivant Shares Rise 6% on Vtama's FDA Approval
Roivant Sciences Ltd (ROIV)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
620
Year Founded
N/A

Company Calendar

Today
7/05/2022
Fiscal Year End
3/31/2023

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+173.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
8 Analysts

Profitability

Net Income
$-845,260,000.00
Net Margins
-1,528.89%
Pretax Margin
-1,670.85%

Debt

Sales & Book Value

Annual Sales
$55.29 million
Book Value
$2.95 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.12 billion
Optionable
Not Optionable
Beta
1.58














Roivant Sciences Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Roivant Sciences stock.
View analyst ratings for Roivant Sciences
or view top-rated stocks.

What is Roivant Sciences' stock price forecast for 2022?

8 brokers have issued 1 year price objectives for Roivant Sciences' stock. Their ROIV stock forecasts range from $7.00 to $15.00. On average, they expect Roivant Sciences' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 167.3% from the stock's current price.
View analysts' price targets for Roivant Sciences
or view top-rated stocks among Wall Street analysts.

How has Roivant Sciences' stock price performed in 2022?

Roivant Sciences' stock was trading at $10.08 at the start of the year. Since then, ROIV stock has decreased by 55.5% and is now trading at $4.49.
View the best growth stocks for 2022 here
.

Who are Roivant Sciences' key executives?

Roivant Sciences' management team includes the following people:
  • Mr. Matthew Gline, CEO & Director (Age 38, Pay $813.55k)
  • Dr. Eric Venker M.D., Pharm.D., Pres & COO (Age 35, Pay $813.55k)
  • Dr. Mayukh Sukhatme M.D., Pres & Chief Investment Officer (Age 46)
  • Mr. Richard Pulik, Chief Financial Officer (Age 43)
  • Ms. Rakhi Kumar, Chief Accounting Officer (Age 42)
  • Mr. Josh Chen, Gen. Counsel
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 54)
  • Dr. Woody Sherman Ph.D., Chief Computational Scientist
  • Mr. Alex Gasner, Exec. VP of Roivant Health
  • Dr. Matt Maisak, Chief Operating Officer of Roivant Platforms

What is Roivant Sciences' stock symbol?

Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

How do I buy shares of Roivant Sciences?

Shares of ROIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Roivant Sciences' stock price today?

One share of ROIV stock can currently be purchased for approximately $4.49.

How much money does Roivant Sciences make?

Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $3.11 billion and generates $55.29 million in revenue each year. The company earns $-845,260,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does Roivant Sciences have?

Roivant Sciences employs 620 workers across the globe.

How can I contact Roivant Sciences?

Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for Roivant Sciences is roivant.com. The company can be reached via phone at 44 4412 955 950.

This page (NASDAQ:ROIV) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.